1.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
by Drilon, Alexander
The lancet oncology, 2020-02, Vol.21 (2), p.261-270
2.
Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials
by Getz, Kenneth A
Clinical therapeutics, 2017-11, Vol.39 (11), p.2203-2213
3.
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
by Wilson, Michelle K, FRACP
The lancet oncology, 2015, Vol.16 (1), p.e32-e42
4.
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
by Anon
The lancet oncology, 2016, Vol.17 (6), p.779-790
5.
Response assessment criteria for brain metastases: proposal from the RANO group
by Lin, Nancy U, Dr
The lancet oncology, 2015, Vol.16 (6), p.e270-e278
6.
Dramatic drop in new cancer drug trials during the COVID-19 pandemic
by Wilkinson, Emma
The lancet oncology, 2021-03, Vol.22 (3), p.305-305
7.
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working gr...
by Camidge, D Ross
The lancet oncology, 2018-01, Vol.19 (1), p.e20-e32
8.
The value of research collaborations and consortia in rare cancers
by Blay, Jean-Yves, Prof
The lancet oncology, 2016, Vol.17 (2), p.e62-e69
9.
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase...
by Tran, Hai T, PharmD
The lancet oncology, 2012, Vol.13 (8), p.827-837
10.
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
by Voss, Martin H
The lancet oncology, 2018-12, Vol.19 (12), p.1688-1698
11.
Precision oncology: A new era of cancer clinical trials
by Renfro, Lindsay A
Cancer letters, 2016, Vol.387, p.121-126
12.
Nivolumab: targeting PD-1 to bolster antitumor immunity
by Brahmer, Julie R
Future oncology (London, England), 2015-05-01, Vol.11 (9), p.1307-1326
13.
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
by Stang, Andreas
European journal of epidemiology, 2010-01-01, Vol.25 (9), p.603-605
14.
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
by Bottomley, Andrew, Dr
The lancet oncology, 2016, Vol.17 (11), p.e510-e514
15.
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
by Takahashi, Toshiaki, MD
The lancet oncology, 2017, Vol.18 (5), p.663-671
16.
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
by Katz, Matthew H. G
Annals of surgical oncology, 2013-02-23, Vol.20 (8), p.2787-2795
17.
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
by Alexander, Brian M
The lancet oncology, 2018-01, Vol.19 (1), p.e33-e42
18.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
by Antonia, Scott J
The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408
19.
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
by van den Bent, MJ, Prof
The lancet oncology, 2011, Vol.12 (6), p.583-593
20.
Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic
by de Paula, Bruno H R
The lancet oncology, 2020-05, Vol.21 (5), p.624-627
Filter electronic articles 5.767 Hits
Remove Filters
- Subjects
- Oncology
- Science & Technology (5.439)
- Life Sciences & Biomedicine (5.433)
- more ...